# Capecitabine

## Capecitabine 500mg

| 藥物代碼 | OCAP5 |
| :--- | :--- |
| 適應症 | Colon cancer, Adjuvant therapy, Duke's Stage C, when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer, metastatic colorectal cancer, 1-line therapy when treatment with a fluoropyrimidine alone is preferred. |
| 副作用 | GI disturbances; hand-foot syndrome, alopecia, pruritus, rash; fatigue, pyrexia, lethargy, asthenia; dizziness, taste disturbance; anorexia; conjunctivitis; neutropenia.Dermatologic: Dermatitis \(27% to 37% \)Gastrointestinal: Abdominal pain, Constipation, Loss of appetite, Nausea, Stomatitis, VomitingOther: Fatigue |
| 禁忌 | Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation; severe renal impairment \(CrCl &lt;30 mL/minute\). Canadian labeling: Additional contraindications \(not in the US labeling\): Known complete absence of dihydropyrimidine dehydrogenase \(DPD\) activity; concomitant administration with sorivudine or chemically related analogues \(eg, brivudine\). |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

